Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference

Adnavance Technologies to Present Initial Data Supporting Direct Detection
Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference

SAN DIEGO, Oct. 8 /PRNewswire/ -- Adnavance Technologies Inc., a developer of
direct detection molecular diagnostic tests for medical applications,
announced today that Randy White, Ph.D. chief executive officer, will present
initial data supporting direct detection of DNA targets in human clinical
samples during company presentations at the following conferences:

-- AdvaMed 2009 on Tuesday, October 13, 2009 at 10:00 a.m. Eastern Time
at
the Walter E. Washington Convention Center in Washington, D.C.

-- BIOCOM's 4th Annual Investor Conference on Monday, October 26, 2009 at
10:00 a.m. Pacific Time at the Hyatt Regency La Jolla in San Diego,
California.

"The hallmark of Adnavance's direct detection technology is its simplicity; it
doesn't require PCR, light detection, or sample pre-treatment. We are highly
encouraged by our initial data supporting the utility of our technology and
its potential for use in medium complexity laboratories," said Dr. White. "Our
mission is to de-centralize molecular diagnostics."

About Adnavance Technologies Inc.
Adnavance is a molecular diagnostic company focused on development of its
proprietary technology that allows direct-detection of DNA targets in human
clinical samples. The Company is located in San Diego, CA. The Company's
patented technology is based on the change in surface charge on a gold
electrode when DNA targets hybridize with capture probes anchored to the
electrode surface. The Company uses a microarray of electrodes in an
electrochemical cell to detect the target DNA and the inherent
ultra-sensitivity of electrochemical measurements obviates the need for target
amplification used in current molecular-based tests. In addition, the
electrochemical measurement simplifies the medical device and eliminates
sample pre-treatment steps required for PCR-based tests. Adnavance scientists
were the first to discover the surface charge phenomenon, and the Company
believes its technology platform will open new molecular testing markets. For
additional information please see the Company website at www.adnavance.com.

Forward-Looking Statements
Certain statements made in this press release are forward-looking. Such
statements are indicated by words such as "expect," "should," "anticipate,"
and similar words indicating uncertainty in facts and figures. Although
Adnavance believes that the expectations reflected in such forward-looking
statements are reasonable, it can give no assurance that such expectations
reflected in such forward-looking statements will prove correct. Actual
results could differ materially from those projected in the forward-looking
statements as a result of the following factors, among others: uncertainties
associated with the technology development process, the risk that Adnavance
technology will not gain market acceptance, the risks associated with
dependence upon key personnel and the need for additional financing to
commercialize the technology platform.

Media Contact:
Kim Richards
Porter Novelli Life Sciences
619-849-5377
krichards@pnlifesciences.com

SOURCE Adnavance Technologies Inc.

Media, Kim Richards of Porter Novelli Life Sciences, +1-619-849-5377,
krichards@pnlifesciences.com